You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Non-Invasive Treatment for Uveitis

    SBC: ACIONT, INC.            Topic: N

    DESCRIPTION provided by applicant The aim of this innovative proposal is to commercialize a non invasive topical product that treats uveitis which is safe and easy to administer Uveitis is the third leading cause of blindness in the United States Heretofore the primary treatment of intermediate and posterior uveitis has been either oral medications with significant systemic side effects or ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Anti-Inflammatory Glycosaminoglycan Ethers for Treatment of Periodontitis

    SBC: GLYCOMIRA, LLC            Topic: NIDCR

    DESCRIPTION provided by applicant Chronic gingival inflammation of the soft tissue surrounding the tooth afflicts over half of all American adults In the most severely affected progression of this inflammatory process to the deeper periodontal ligaments and alveolar bone results in tooth loss from loss of mandibular anchorage Gingivitis and periodontitis are initiated by chronic infection o ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Long-Acting G-CSF Analog for Treating ARS

    SBC: BOLDER BIOTECHNOLOGY INC            Topic: NIAID

    DESCRIPTION provided by applicant Development of radiological nuclear medical countermeasures to treat Acute Radiation Syndrome ARS is a high priority research area for NIAID Bone marrow is one of the most sensitive tissues to radiation damage and impaired hematopoiesis is one of the first clinical signs of excessive radiation exposure often resulting i death Granulocyte colony stimulating ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Therapeutic D-peptide Inhibitor of HIV Entry

    SBC: NAVIGEN, INC.            Topic: NIAID

    DESCRIPTION provided by applicant With million people living with HIV AIDS including million in the US and million AIDS related deaths annually HIV AIDS remains a formidable global epidemic UNAIDS CDC Modern HIV therapy combines drugs from different classes to form andquot cocktailandquot therapies that have significantly prolonged the lives of many HIV patients However side effects and drug resis ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  5. A Child's Body-Powered Prehensor with Adaptive Grasp

    SBC: ADA TECHNOLOGIES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Conventional body-powered assistive appliances intended to help children having upper limb deficiencies have proven inadequate for some activities, most notably play. The critical component in these systems that contributes grasp functionality, called a prehensor or terminal device, must strike a balance between functionality for activities children wish to ac ...

    SBIR Phase II 2007 Department of Health and Human ServicesNational Institutes of Health
  6. Lung Drug Delivery with Carbon Dioxide Aerosol Inhalers

    SBC: AEROPHASE, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Asthma is one of the most common and costly illnesses in the US, with over 20 million Americans suffering from asthma with an annual societal cost of over $18 billion. Sadly, about 5000 Americans die every year from asthma, even though most asthma death is preventable with proper treatment, and the rates are especially high among the socioeconomically disadvant ...

    SBIR Phase II 2007 Department of Health and Human ServicesNational Institutes of Health
  7. Mr. Vetro: A Collective Simulation Framework for Health Science Education

    SBC: Agentsheets, Inc            Topic: N/A

    DESCRIPTION (provided by applicant): Science apathy is growing at the K-12 education level, and represents an alarming development with potentially devastating consequences at individual, societal and economic levels. Surprisingly, this student apathy is increasing while the general public reads record numbers of popular science books and watches increasing amounts of science TV programming. In sp ...

    SBIR Phase II 2007 Department of Health and Human ServicesNational Institutes of Health
  8. Commercialization of Graphical Display for Critical Care Environments

    SBC: APPLIED MEDICAL VISUALIZATIONS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The objective of this project is to develop and test information visualization display technology that will aid clinicians in diagnosing and treating unexpected events in critical care environments. Unexpected events occur frequently in the ICU and many are related to missing, inaccurate or misinterpreted information. In a one year study of 1024 patients in an ...

    SBIR Phase II 2007 Department of Health and Human ServicesNational Institutes of Health
  9. Commercialization of a Graphical Pharmacokinetic-Pharmacodynamic Display

    SBC: APPLIED MEDICAL VISUALIZATIONS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Applied Medical Visualizations L.L.C. has developed a pharmacokinetic-pharmacodynamic display (PkPd Display) intended for anesthesia care providers. In Phase I, we designed a display that was based on a two drug interaction model, which was previously developed for an opioid (remifentanil) and a sedative hypnotic (propofol) in human volunteers. The measures for ...

    SBIR Phase II 2007 Department of Health and Human ServicesNational Institutes of Health
  10. Long Acting IFN-gamma for Treating Immunodeficiencies

    SBC: BOLDER BIOTECHNOLOGY INC            Topic: N/A

    DESCRIPTION (provided by applicant): Interferon-gamma is a T cell-derived cytokine that exhibits anti-viral and immunomodulatory effects on many cell types. Recombinant human interferon-gamma is approved for the treatment of chronic granulomatous disease and severe malignant osteopetrosis. Other indications currently being investigated in human clinical trials include idiopathic pulmonary fibrosis ...

    SBIR Phase II 2007 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government